🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Come join us at Biotechnology Innovation Organization #BIO2024 event June 3-6 in San Diego to meet Olatec’s team to learn about lead candidate, dapansutrile’s, clinical position as a leader in the potential #NLRP3inhibitor class for both acute & chronic inflammatory diseases convention.bio.org/sessions/olate…

Olatec has been selected to present Biotechnology Innovation Organization #BIO2024 event on June 4 at 3:45p in Theater 3. Please join our CMO, Dr. #MustafaNoor who will discuss the clinical status and data on our #NLRP3inhibitor #dapansutrile in #gout, #cardiometabolic and #neuroinflammatory diseases.

Olatec’s CMO #MustafaNoor & team will be presenting Biotechnology Innovation Organization #BIO2024 event on June 4 at 3:45p in Theater 3 to discuss Olatec’s clinical development of its #NLRP3inhibitor, #dapansutrile, including data to-date and near-term milestones. convention.bio.org/sessions/olate…

The first patient has been enrolled in a Phase 2 study for Type 2 Diabetes using Olatec's NLRP3 Inhibitor, Dapansutrile. More Info: pryzm.ozmosi.com/product/3875 $XBI $IBB $XPH $PPH

The first patient with type 2 diabetes and diabetes-related complications has been enrolled in a clinical trial called DAPAN-DIA in Basel, Switzerland, with Olatec’s NLRP3 inhibitor, dapansutrile, which is sponsored by Principal Investigator, #MarcDonath prnewswire.com/news-releases/…

We were pleased to present at the @Biocentury Grand Rounds event this week where we discussed translating #NLRP3Inflammasome inhibition into clinical therapeutics and the clinical status and data on our specific #NLRP3inhibitor #dapansutrile

Olatec has been invited to present a scientific poster on dapansutrile, an #NLRP3inhibitor in clinical development in multiple diseases driven by inflammation at #EMBOinflammasomes24. The EMBO Workshop is bringing researchers together to advance inflammasome biology on Sept. 24

#IsakTengesdal presented EMBO on the need for new assays to reliably assess #NLRP3inhibitors outside of sulfonylureas chemotypes. For example, a new assay called NLRP3 NanoBRET®, doesn't account for the unique chemotype of these inhibitors, like #dapansutrile a sulfonylnitrile

In their recent Eric Zurrin paper, Tengesdal et al. (2024) highlight the crucial limitations of the NLRP3 NanoBRET® assay in evaluating inhibitors with non-sulfonylurea chemotypes like #dapansutrile. Improved methods are essential for accurate screening. #EMBOinflammasomes24

Isak Tengesdal is at #ACR24 American College of Rheumatology in Washington, DC, showcasing advancements in #rheumatology, including our ongoing PODAGRA-II (NCT05658575) clinical trial. See abstract (0934) here. Join us tomorrow, Sunday, November 17, from 10:30 AM to 12:30 PM. acrabstracts.org/abstract/scree…

cureparkinsons.org.uk/2024/11/the-bi… Dapansutrile: a new hope for Parkinson’s? An exciting phase 2 clinical trial of dapansutrile (DAPA-PD), an anti-inflammatory drug, to determine whether it has the potential to slow the progression of Parkinson’s.

Our #ChristmasChallenge via @TheBigGive is now live! This #GivingTuesday, support #CureParkinsons between now and midday 10 December and your donations will be doubled! You'll be helping us fund a phase 2 clinical trial of dapansutrile. Donate now: buff.ly/3ZfmKQh

The Big Give We'll be examining whether dapansutrile (DAPA-PD), an anti-inflammatory drug, has the potential to slow the progression of Parkinson’s. Our sole aim is to find a cure – this trial could bring us closer to achieving this. Find out more below: buff.ly/3VjClwW

A great review of Cure Parkinson's research activities in 2024 & things to look out for in 2025! Very proud of the whole team - small charity, doing big things for #Parkinsons research focused on disease modification! cureparkinsons.org.uk/2025/01/2025-r…

What about 'inflammasome inhibitors' as a treatment for Parkinson's? There is a lot of interest in new drugs like NT-0796, Selnoflast, Dapansutrile, VTX 3232 and ZYIL1. Bina Patel and colleagues summarize this and more in a new study in Journal of Parkinson's Disease. Key Points: - The authors

Long-time collaborator and advisor, Prof. Dr. Marc Donath, has joined the Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, Clinical Advisory Board. businesswire.com/news/home/2025…

The drug was well-tolerated, with no major safety concerns. Researchers are now preparing to test another anti-inflammatory therapy—dapansutrile—to continue this promising line of investigation. Powered by @parkinsonsuk #parkinson #parkinsonsdisease #parkinsonsawareness

The Society's Crystal Clear campaign aims to help those suffering from gout understand their diagnosis and why education matters! Hear from experts and members of our Board and IAC, on what they would like gout sufferers to by crystal clear about when it comes to managing gout!